Evidence map›Paper›PMID 31049357›Full record

ArticleJournal of diabetes research2019

Inhibition of Aberrant IGF-I Signaling in Diabetic Male Rat Retina Prevents and Reverses Changes of Diabetic Retinopathy.

Gang Xi, Christine Wai, David Clemmons

Open access · goldAbstract read
In one paragraph

Article in Journal of diabetes research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gang XiDivision of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Christine WaiDivision of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
David ClemmonsDivision of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.ORCID 0000-0001-9946-788X
University of North Carolina at Chapel Hill · US

Funding

Development of a novel method for inhibiting diabetic retinopathyR42EY021943 · NEI · CMP TARNHELM PARTNERS, LLC · PI CLEMMONS, DAVID R · 2015 to 2016
$1.2M
Development of a novel method for inhibiting diabetic retinopathyR41EY021943 · NEI · VASCULAR PHARMACEUTICALS · PI CLEMMONS, DAVID R · 2012 to 2012
$173k
NEI NIH HHS R41 EY021943NEI NIH HHS R42 EY021943
6 · The paper itself

Abstract

Hyperglycemia results in inhibition of cleavage of integrin-associated protein (IAP) thereby allowing it to bind to SHPS-1 which results in pathophysiologic changes in endothelial function. This study determined if an anti-rat IAP antibody directed against the SHPS-1 binding site which disrupts IAP/SHPS-1 association could inhibit these pathophysiologic changes. The anti-IAP antibody inhibited IGF-I-stimulated SHPS-1, p52Shc, MAP kinase phosphorylation, and proliferation in endothelial cells. To determine if it could reverse established pathophysiologic changes in vivo, this antibody or normal rat IgG F(ab)2 was injected intraperitoneally for 6 weeks into rats that had diabetes for 4 weeks. Optical coherence tomography (OCT) showed that retinal thickness increased at 4 weeks and this increase was maintained in rats treated with the control antibody for an additional 6 weeks. The increase was reversed by anti-IAP antibody treatment (84.6 ± 2.0 compared to 92.3 ± 2.5

Indexed as

AnimalsAntibodiesCell ProliferationCells, CulturedDiabetes Mellitus, ExperimentalDiabetic RetinopathyEndothelial CellsInsulin-Like Growth Factor IMaleProto-Oncogene Proteins c-aktRatsRats, Sprague-DawleyRetinaSignal TransductionTomography, Optical CoherenceAntibodiesInsulin-Like Growth Factor IProto-Oncogene Proteins c-akt

Identifiers

PMID31049357
PMCPMC6458945
OpenAlexW2923682415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.